job cuts, layoffs

Magenta Therapeutics is reducing the company’s workforce by 14 percent in a revised operating plan to prioritize research and development.


AstraZeneca said the company’s Enhertu cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a much larger potential patient group.

Mersana Therapeutics signed a research and licensing deal with Janssen Biotech to access each other’s proprietary technology in discovering new antibody-drug conjugates (ADCs) for three cancer targets. 

Seagen (formerly known as Seattle Genetics) forged an exclusive licensing agreement with China’s RemeGen to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC).

Daiichi Sankyo and AstraZeneca reported positive topline data from their head-to-head DESTINY-Breast-03 Phase III trial for Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2 positive metastatic breast cancer.

Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.

A new study by researchers at the University College London (UCL) published in Lancet Infectious Diseases finds that although the U.K. variant of SARS-CoV-2 known as B.1.1.7 is more transmissible than the wild-type, original Wuhan strain, it is likely not more deadly.

Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.